ArticleFrontiers in pharmacology2025
The effective sedative dose of remimazolam for BIS <60 during general anesthesia induction between elderly and non-elderly patients-A randomized controlled trial.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is lack research about the effect of sufentanil on the effective dose of remimazolam during general anesthesia in both elderly and non-elderly patients scheduled for day surgery. This study was conducted to estimate the 95% effective dose (ED95) of remimazolam with low dose of sufentanil for BIS <60 during general anesthesia in both elderly and non-elderly patients scheduled for day surgery. Methods: Patients scheduled for elective gynecological day procedures were randomly allocated to one of four dosage groups receiving 0.1, 0.2, 0.3, or 0.4 mg/kg of remimazolam, with 25 participants per group. All patients received a concurrent intravenous dose of sufentanil (0.1 μg/kg) during anesthesia induction. Successful sedation was defined as achieving a BIS score of <60 within 5 minutes of remimazolam administration. The ED50 and ED95 of remimazolam for BIS <60 during general anesthesia induction were calculated. Secondary outcomes included the incidence of hypotension, respiratory depression, and adverse events. Results: In elderly patients, the estimated ED50 of remimazolam was determined to be 0.156 mg/kg, with a 95% confidence interval (CI) ranging from 0.110 to 0.190 mg/kg. For non-elderly individuals, the corresponding ED50 was 0.218 mg/kg (95% CI: 0.179-0.253 mg/kg). Additionally, the dose required to achieve 95% efficacy (ED95) was calculated as 0.336 mg/kg (95% CI: 0.286-0.437 mg/kg) in the elderly cohort and 0.418 mg/kg (95% CI: 0.361-0.528 mg/kg) in the non-elderly cohort. Hypotension occurred significantly more often in elderly patients ( Conclusion: Under BIS monitoring during gynecological day surgery, the estimated ED95 of remimazolam with 0.1 μg/kg sufentanil was 0.336 mg/kg (95% CI: 0.286-0.437 mg/kg) for elderly patients and 0.418 mg/kg (95% CI: 0.361-0.528 mg/kg) for non-elderly patients. Clinical Trial Registration: This study is registered with ClinicalTrials.gov as ChiCTR2400091138.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.